Veristat Announces Global Cell and Gene Therapy Center of Excellence
Accelerating cell and gene therapy opportunities for patients by advancing access to knowledge and leveraging experience for sponsors to...
Veristat Launches A Flexible Virtual Clinical Trial Solution
Veristat Enhances Patient-Centricity Offering by Delivering Clinical Trials Directly to Patients
SOUTHBOROUGH, MA – September 30, 2020 – ...
Veristat Helps Antibe Therapeutics Complete Their Phase IIB Study During COVID-19
In early 2019, Veristat helped Antibe Therapeutics, a biotech company with a drug platform of game-changing therapeutics in pain and...
Veristat Strengthens Its European Presence with the Acquisition of TCTC
Increasing Its Footprint and Expanding Therapeutic Expertise to Guide Sponsors Throughout the Clinical Development Lifecycle
Veristat Strengthens Its Regulatory Expertise with the Acquisition of Catalyst Regulatory...
Expanding Its Team of Regulatory Experts to Guide Biopharmaceutical Sponsors Along the Pathway to Market Approval
Veristat Expands Operations into Taiwan
Veristat Expands Operations into Taiwan to Support Growing Client Demand for Clinical Trial, Biostatistics and Programming Excellence in the...
Veristat Advances Game-Changing Pain and Inflammation Therapy
Veristat continues to support Antibe Therapeutics, a biotech company with a drug platform of game-changing therapeutics in pain and...
Veristat Supports 12% of all FDA NME Approvals in 2018, a Record-Setting Year for FDA...
Veristat Celebrates Its Support of over 75 Global Regulatory Submissions Since Its Founding
Veristat Supports Antibe Therapeutics for Pain and Inflammation Study
Upon receiving approval from Health Canada, Antibe Therapeutics selected Veristat to immediately begin work on part one of a Phase 2B...